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include drug costs, drug administration costs, physician charges
for monitoring, and cost for dialysis or kidney transplants for
those progressing to ESRD. Costs were modiﬁed to 2003 US$
using the medical care component of the Consumer Price Index
adjustment for inﬂation ratio, and discounted at 3%. Cost were
calculated on a per patient basis and then annualized. Statistical
comparisons of costs were done using a nonparametric Mann-
Whitney U test. Sensitivity analyses were also performed.
RESULTS: Lupus nephritis patients receiving azathioprine plus
prednisone had signiﬁcantly lower overall treatment costs,
demonstrating a $14,580 cost savings per patient over the 10-
year evaluation period. The Mann-Whitney U test indicated that
the azathioprine and cyclophosphamide arm costs $101,003.25
and $115,583.54, correspondingly were signiﬁcantly different 
(P = 0.0091, 95% CI: $482, $2484). The mean difference
between the treatment arms was $1453. Sensitivity analyses con-
ducted on the drug costs, and the probability of discontinuation
of cyclophosphamide did not change the results of the model.
CONCLUSIONS: The results indicate that azathioprine signiﬁ-
cantly reduced the total long-term costs to the third party 
payer. The decision analysis supports the use of azathioprine 
plus prednisone as induction therapy in the treatment of lupus
nephritis.
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OBJECTIVE: Uncomplicated urinary tract infections are a
highly prevalent condition among college-age women. In addi-
tion, resistance to commonly used treatments is increasing. This
study compares antibiotic cost-effectiveness at a college health
clinic. METHODS: Treatment encounters at the clinic were
reviewed for prescribing and effectiveness data. Cost estimates
include provider visit, laboratory costs, and the cost of pre-
scribed medication. Two decision-analysis models were con-
structed, one including all relevant costs and the other including
only the portion of the cost absorbed by the health clinic.
RESULTS: There were 436 cases of urinary tract infection at the
health clinic in 2001–2002. Cases were included if they were
uncomplicated and there was no prior antibiotic allergy, resis-
tance, or risk factors for resistance. Of the 91 included cases, 51
were treated with sulfamethoxazole/trimethoprim (SMX/TMP),
33 were treated with nitrofurantoin and 7 were treated with
ciproﬂoxacin. Cost-effectiveness results were based on evalua-
tion of drug cost, potential for allergy, and clinical cure rates.
Despite 23% laboratory resistance and 9% allergy, 79% of
patients treated with SMX/TMP were successfully cured. Nitro-
furantoin was effective in 97% of patients and ciproﬂoxacin was
effective in 100% of patients with few cases of allergy. Treat-
ment cost per patient was $144 for SMX/TMP, $169 for nitro-
furantion and $173 for ciproﬂoxacin. The cost per patient
absorbed by the health clinic was $55 for SMX/TMP and $65
and $58 for nitrofurantoin and ciproﬂoxacin respectively. CON-
CLUSIONS: Most of the patients treated with SMX/TMP were
successfully cured, despite increasing laboratory resistance rates.
We found SMX/TMP to be the most cost-effective treatment for
uncomplicated urinary tract infections. It is important to remem-
ber the importance of clinical success and laboratory resistance
when constructing such models, and the results are likely to vary
widely.
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OBJECTIVES: To study the impact of EPO therapy on direct
medical cost by comparing anemic NDCKD patients treated with
EPO to those not treated. METHODS: Anonymous medical and
pharmacy claims data in January 1998–June 2001 from seven
large companies were used. After excluding patients receiving
blood transfusions, 66 NDCKD patients with at least two
anemia claims were identiﬁed as anemic. Of them, 30 patients
treated with EPO prior to dialysis were classiﬁed as the EPO
group, while the remaining 36 were the control group. Descrip-
tive statistics were generated to compare the direct medical cost
of the EPO and control groups prior to dialysis and in the ﬁrst
six months after dialysis initiation. RESULTS: Baseline age,
gender, and comorbidities did not signiﬁcantly differ between 
the two groups. The average monthly total medical cost for 
the control group was higher than that for the EPO group in
both the pre- and post-dialysis phases ($2916.5 vs. $2177.9,
$11,245.7 vs. $10,143.8, respectively), albeit not reaching a 5%
signiﬁcance level. Before dialysis, the monthly inpatient and out-
patient costs were higher in the control than EPO group
($1541.8 vs. $795.2 inpatient, p > 0.05; $1247.3 vs. $918.8 out-
patient, p < 0.05). In contrast, average monthly drug cost was
higher for the EPO group ($463.9 vs. $127.4, p < 0.05). Similar
patterns were observed in the dialysis phase. CONCLUSIONS:
An overall trend in the reduction of medical cost was seen for
EPO-treated anemic NDCKD patients compared to those not
treated. The cost savings for the EPO group for inpatient and
outpatient services outweigh the higher drug cost. Although the
differences in total medical cost are not statistically different
between EPO and control groups, this may be due to the small
sample size. Further research with larger samples are warranted.
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OBJECTIVES: Prevalence rates of 16% have been reported for
overactive bladder (OAB). Despite the high prevalence of OAB,
it is both an under-diagnosed and underreported condition. Once
symptoms develop, many individuals construct their preferences
for treatment after considering the quality of life (QOL) effects
of OAB and whether they possess prescription drug insurance.
The purpose of this study was to examine the relative impor-
tance patients place on QOL domains and prescription drug 
coverage in their decision to pharmacologically manage OAB
symptoms. METHODS: A questionnaire consisting of nine
hypothetical proﬁles was used to elicit preferences. The sample
taken from a large clinic consisted of 134 patients having symp-
toms of OAB. To be included, participants were either male or
female and were not taking medications to treat their symptoms.
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Data were obtained via self-administered questionnaire and tele-
phone using trained interviewers. QOL domains used were those
identiﬁed by the OAB-q instrument developed by Coyne et al.
All proﬁle attributes had two levels: high/present and low/not
present. RESULTS: The linear ﬁxed-effects model resulted in the
following part-worth coefﬁcients for the ﬁve attributes of inter-
est: insurance coverage, 34.17; sleep, 23.55; concern, 19.59;
social, 19.28; coping, 15.61. Also reported is an analysis of
demographic variables with respect to symptom severity and
QOL. CONCLUSIONS: When deciding to treat OAB symptoms
with prescription medications, patients place the most impor-
tance on prescription drug insurance coverage. QOL domains
follow insurance in this order: sleep disturbances, symptom
concern, social disturbances, and coping.
URINARY/KIDNEY DISEASES/DISORDERS
URINARY/KIDNEY DISEASES/DISORDERS—Health
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OBJECTIVES: To assess patient persistency in maintaining treat-
ment for Overactive Bladder (OAB). METHODS: Patients initi-
ating therapy on oxybutynin or tolterodine, immediate or
extended release, were tracked for 12-months, using a retail
pharmacy database. Five persistency classiﬁcation categories
were created to evaluate persistency as follows: on therapy, dis-
continued/no switch, discontinued/switched to one of the other
previously listed medications, reinitiated initial therapy, and off
therapy. Measurements included tracking the percent of patients
within each persistency classiﬁcation category, total therapy
days, and prescriptions dispensed for all medications. RESULTS:
The percentage of patients that discontinued their current
therapy and did not switch to another OAB therapy was 46.9%
at month three. By month four, more than half of all patients
were off therapy (55.4%). The percentage of patients off therapy
increased each month and reached 81.6% by the end of twelve
months. The percentage of patients that were switched to
another OAB medication did not exceed 3% in any month, nor
did the percentage of patients who reinitiated their initial therapy
surpass 3% in any month. The mean length of therapy was
approximately 86 days, with an average days supply of 30.
Approximately half of all patients were dispensed only one 
medication during the 12-month period. CONCLUSIONS:
Patient persistency with any currently marketed medications for
OAB remains poor, with less than 20% of study patients remain-
ing on therapy after 1 year.
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OBJECTIVES: The objectives of PURE are to understand the
direct cost of urinary incontinence (UI); describe the impact of
UI on health-related quality of life (HRQOL); and describe the
treatment patterns for women with UI in Europe in an outpa-
tient setting. METHODS: PURE is an ongoing, prospective,
observational study. More than 9000 patients will be recruited
in 13 European countries. The participating investigators are
primary care physicians and specialists (urologists, gynaecolo-
gists, geriatricians). The data will be prospectively collected at
baseline and at 2 points over a 6-month period. Assessments
include health care resource utilisation and treatments to derive
direct medical costs of UI care and describe the treatment pat-
terns, as well as symptoms and severity of UI and impact of UI
on patients’ lives. Baseline evaluation will additionally include
demographics, medical history, the assessment of HRQOL and
a retrospective data collection on health care resource utilisation
in the previous 12 months. RESULTS: By considering all the 10
priority research areas on the economics of UI identiﬁed by the
2nd international consultation on incontinence, PURE provides
a unique opportunity to assess the direct medical costs for UI
care in women across Europe. This will give insights to the eco-
nomic burden from the perspective of the national health care
systems, as well as from the patient, and will allow comparisons
of treatment patterns between countries in the light of different
health care systems and access to care. To our knowledge this is
the ﬁrst study undertaken in an outpatient setting to investigate
the economic and human impact of UI in Europe. CONCLU-
SIONS: PURE will address relevant clinical, economic and policy
research questions and will provide large-scale, comparative,
real-world information on the treatment and burden of UI across
Europe; data currently missing from the European literature but
needed to guide effective health policy.
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OBJECTIVES: Acute renal failure (ARF) is a prevalent and 
often preventable adverse drug event. Automated methods for
ARF identiﬁcation facilitate quality improvement and outcome
research, but traditional reliance on ICD9 codes has been shown
to underestimate the incidence. This study aimed to develop and
validate automated algorithms for the identiﬁcation of hospital-
acquired ARF. METHODS: A panel (nephrologist, internist,
clinical pharmacy specialist, pharmacoepidemiologist, database
analyst) deﬁned 3 algorithms based on existing literature and
available automated data: 1) 50% increase of serum creatinine
(SCr) within 3 days; 2) 50% SCr decrease between peak and 
discharge; and 3) ICD9 584.•• and charge code for dialysis. 
Each algorithm was linked (temporally and proximately) to 
drug exposure (aminoglycosides, amphotericin, cyclosporine,
tacrolimus, NSAIDs, or radiocontrast). Discharges with hospital
days <2 or ESRD (dialysis in ﬁrst 3 days of admission) were
excluded. Algorithms were applied to the laboratory and admin-
istrative databases of a large teaching hospital including dis-
charges between July 1, 2001 and June 30, 2002 (n = 20,639 or
10,536 with nephrotoxic drugs). Senior nephrology fellows to
verify the algorithms reviewed a random sample of positive
screened discharges. A random 20% of these were re-reviewed
